8-K: Delcath Systems Announces Positive Independent Study Results for Liver Cancer Treatments

Delcath Systems reports promising outcomes from two independent studies highlighting the efficacy of their CHEMOSAT and HEPZATO KIT systems in treating liver tumors and uveal melanoma.

Summary

• Delcath Systems announced results from two independent studies showcasing the effectiveness of their liver cancer treatments.
• One study, conducted in Germany, focused on repeated chemosaturation using the CHEMOSAT system for various liver tumors, including uveal melanoma, cholangiocarcinoma, and hepatocellular carcinoma.
• This study reported a 91% disease control rate, with 18.2% of patients achieving complete response in the liver.
• The median hepatic progression-free survival was 52 weeks overall, with 69 weeks for uveal melanoma and 38 weeks for cholangiocarcinoma.
• The second study, conducted at Moffitt Cancer Center, evaluated the HEPZATO KIT for metastatic uveal melanoma.
• This study found that HEPZATO KIT provided better disease control and improved progression-free survival compared to immunotherapy and other liver-directed therapies.
• Patients receiving HEPZATO KIT as first-line therapy had a median overall survival of 22.4 months and a median hepatic progression-free survival of 17.6 months.
• When used as a second-line therapy, HEPZATO KIT resulted in a median hepatic progression-free survival that was not reached, outperforming other treatments.

Sentiment

Score: 9

Explanation: The document presents very positive results from independent studies, indicating significant potential for Delcath's treatments. The high disease control rates and improved survival metrics suggest a strong outlook for the company's products.

Positives

• The CHEMOSAT system demonstrated a high disease control rate of 91% in a study of various liver tumors.
• The study on CHEMOSAT showed that repeated treatments were well-tolerated and resulted in long-term disease control.
• The HEPZATO KIT showed improved overall survival and progression-free survival compared to other treatments for metastatic uveal melanoma.
• The HEPZATO KIT study showed that it was effective as both a first-line and second-line therapy.
• Both studies were conducted independently, adding credibility to the results.

Negatives

• The CHEMOSAT study reported that treatment was discontinued in 2 patients due to adverse events.
• Two patients withdrew consent during the CHEMOSAT treatment period.

Risks

• The CHEMOSAT study noted transient hematological adverse events, which were managed with supportive care.
• The HEPZATO KIT study, while positive, is retrospective and may not fully represent the outcomes in a prospective trial.
• The studies were conducted on a limited number of patients, which may affect the generalizability of the results.

Future Outlook

The company plans to continue exploring and refining the treatment approach in larger, prospective trials and is committed to further exploring the potential of combining melphalan/HDS with systemic therapies to continue improving patient outcomes.

Management Comments

• Dr. Vojislav Vukovic, Chief Medical Officer of Delcath Systems, stated that the results of the independent study reinforce the potential of their CHEMOSAT Hepatic Delivery System as an essential tool in the management of primary and secondary liver tumors.
• Jonathan Zager, MD, Chief Academic Officer and Director of Regional Therapies at Moffitt Cancer Center, remarked that the findings from the study reaffirm the critical role of melphalan/HDS in managing liver-dominant metastatic uveal melanoma.

Industry Context

These announcements are significant in the interventional oncology space, particularly for liver cancer treatments. The results suggest that Delcath's proprietary systems, CHEMOSAT and HEPZATO KIT, offer a viable alternative to traditional therapies, especially for patients with limited treatment options. The studies highlight the potential for improved outcomes in a challenging patient population.

Comparison to Industry Standards

• The CHEMOSAT study's 91% disease control rate is notably high compared to typical outcomes for advanced liver cancers, where disease control rates often range from 30-60% with systemic chemotherapy.
• The median hepatic progression-free survival of 69 weeks for uveal melanoma patients in the CHEMOSAT study is significantly longer than the typical 6-12 months seen with standard treatments.
• The HEPZATO KIT study's median overall survival of 22.4 months as a first-line therapy for metastatic uveal melanoma is a substantial improvement over the 12-18 months often reported with other therapies like immunotherapy.
• The study's finding that HEPZATO KIT as a second-line therapy resulted in a median hepatic progression-free survival that was not reached is a very positive result, indicating a potential for long-term disease control in patients who have failed other treatments.
• These results compare favorably to companies like Sirtex Medical, which offers Y-90 radioembolization for liver cancer, where median survival is often in the 10-15 month range for similar patient populations. The results also compare favorably to companies like Imugene, which is developing oncolytic virus therapies, where clinical trials are still in early stages and results are not as mature.

Stakeholder Impact

• Shareholders are likely to react positively to the promising study results, potentially increasing the company's stock value.
• Patients with liver cancer and uveal melanoma may benefit from these treatments, offering new hope for improved outcomes.
• Healthcare providers may be more inclined to adopt Delcath's systems based on the positive study results.
• The company's employees may experience increased job security and opportunities due to the positive developments.

Next Steps

• The company plans to continue exploring and refining the treatment approach in larger, prospective trials.
• The company is committed to further exploring the potential of combining melphalan/HDS with systemic therapies to continue improving patient outcomes.

Key Dates

Keywords

Hepatic Chemosaturation, Hepatic Perfusion, Liver Cancer, Uveal Melanoma, CHEMOSAT, HEPZATO KIT, Melphalan, Interventional Oncology, Metastatic Liver Cancer, Disease Control Rate, Progression-Free Survival, Overall Survival